Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors - Hyman, D M; Rizvi, N; Natale, R (Clin Cancer Res, 2018)